ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

(2021) Dan Turner et al.   GASTROENTEROLOGY

ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease

(2021) T Kucharzik et al.   Journal of Crohns & Colitis

ECCO Topical Review: Refractory Inflammatory Bowel Disease

(2021) Tim Raine et al.   Journal of Crohns & Colitis

Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease

(2020) David J. Gibson et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

(2020) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis

(2020) Pablo Olivera et al.   GASTROENTEROLOGY

Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial

(2020) Xavier Roblin et al.   GUT

Quality of care standards in inflammatory bowel diseases: a European Crohn’s and Colitis Organisation (ECCO) position paper

(2020) Gionata Fiorino et al.   Journal of Crohns & Colitis

ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology

(2020) Fernando Magro et al.   Journal of Crohns & Colitis

Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications

(2020) Laura E Targownik et al.   Journal of Crohns & Colitis

A Global, Prospective, Observational Study Measuring Disease Burden and Suffering in Patients with Ulcerative Colitis Using the Pictorial Representation of Illness and Self-Measure Tool

(2020) Subrata Ghosh et al.   Journal of Crohns & Colitis

Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn’s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource

(2020) Evangelos Stournaras et al.   GUT

Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomized RIVETING Trial

(2020) Séverine Vermeire et al.   Journal of Crohns & Colitis

Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation

(2019) Mark T. Osterman et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis

(2019) Lieven Pouillon et al.   Journal of Crohns & Colitis

European Crohn’s and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Disease

(2019) Joana Torres et al.   Journal of Crohns & Colitis

Direct and Indirect Costs of Inflammatory Bowel Disease: Ten Years of Follow Up in a Danish Population-Based Inception Cohort

(2019) Bobby Lo et al.   Journal of Crohns & Colitis

Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study

(2019) Sanjay K Murthy et al.   GUT

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study

(2019) Nicholas A Kennedy et al.   Lancet Gastroenterology & Hepatology

Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis

(2019) William J. Sandborn et al.   GASTROENTEROLOGY

Perioperative dietary therapy in inflammatory bowel disease

(2019) Michel Adamina et al.   Journal of Crohns & Colitis

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2019) Bruce E. Sands et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

(2019) Bruce E. Sands et al.   NEW ENGLAND JOURNAL OF MEDICINE

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme

(2019) William J. Sandborn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis

(2019) Omoniyi J. Adedokun et al.   Clinical Gastroenterology and Hepatology

Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors’ reply

(2018) S. Bonovas et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease

(2018) James D Lewis et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases

(2018) Bella Ungar et al.   Clinical Gastroenterology and Hepatology

Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis

(2018) Hans Herfarth et al.   GASTROENTEROLOGY

Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases

(2018) Julien Kirchgesner et al.   GASTROENTEROLOGY

Second N-ECCO Consensus Statements on the European Nursing Roles in Caring for Patients with Crohn’s Disease or Ulcerative Colitis

(2018) Karen Kemp et al.   Journal of Crohns & Colitis

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detections of complications

(2018) Christian Maaser et al.   Journal of Crohns & Colitis

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects

(2018) Andreas Sturm et al.   Journal of Crohns & Colitis

Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials

(2018) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort—An Epi-IBD Study

(2018) Johan Burisch et al.   Journal of Crohns & Colitis

Therapeutic Drug Monitoring During Induction of Anti–Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

(2017) Konstantinos Papamichael et al.   INFLAMMATORY BOWEL DISEASES

Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease

(2017) Orlaith B. Kelly et al.   INFLAMMATORY BOWEL DISEASES

Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease

(2017) Magali Lemaitre et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort

(2017) Johan Burisch et al.   Journal of Crohns & Colitis

Endoscopic and Histological Mucosal Healing in Ulcerative Colitis in the First Year of Diagnosis: Results from a Population-based Inception Cohort from Six Countries in Asia

(2017) Choy May Leung et al.   Journal of Crohns & Colitis

DOP001 European Crohn's and Colitis Organisation topical review on environmental factors in IBD

(2017) C. Maaser et al.   Journal of Crohns & Colitis

Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial

(2017) David T. Rubin et al.   Journal of Crohns & Colitis

European Crohn’s and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease

(2017) Patrick F van Rheenen et al.   Journal of Crohns & Colitis

European Crohn’s and Colitis Organisation Topical Review on Treatment Withdrawal [‘Exit Strategies’] in Inflammatory Bowel Disease

(2017) Glen Doherty et al.   Journal of Crohns & Colitis

Research Gaps in Diet and Nutrition in Inflammatory Bowel Disease. A Topical Review by D-ECCO Working Group [Dietitians of ECCO]

(2017) Rotem Sigall-Boneh et al.   Journal of Crohns & Colitis

Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study)

(2017) Toshifumi Hibi et al.   JOURNAL OF GASTROENTEROLOGY

Budesonide foam for mild to moderate distal ulcerative colitis: A systematic review and meta-analysis

(2017) Jian Zeng et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial

(2016) B. G. Feagan et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis

(2016) B. Ungar et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis

(2016) Konstantinos Papamichael et al.   Clinical Gastroenterology and Hepatology

Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions

(2016) Laurent Peyrin-Biroulet et al.   Clinical Gastroenterology and Hepatology

ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update

(2016) Silvio Danese et al.   Journal of Crohns & Colitis

Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis

(2016) Konstantinos Papamichael et al.   Journal of Crohns & Colitis

Current best practice for disease activity assessment in IBD

(2016) Alissa J. Walsh et al.   Nature Reviews Gastroenterology & Hepatology

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed

(2015) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies

(2015) W. J. Sandborn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab

(2015) Henit Yanai et al.   Clinical Gastroenterology and Hepatology

Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis

(2015) David T. Rubin et al.   DIGESTIVE DISEASES AND SCIENCES

Budesonide Foam Induces Remission in Patients With Mild to Moderate Ulcerative Proctitis and Ulcerative Proctosigmoiditis

(2015) William J. Sandborn et al.   GASTROENTEROLOGY

Systematic Review

(2015) Russell D. Cohen et al.   INFLAMMATORY BOWEL DISEASES

Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis

(2015) Xue-Liang Jiang et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

The Impact of Endoscopic Inflammation and Mucosal Healing on Health-related Quality of Life in Ulcerative Colitis Patients

(2015) Klaus Theede et al.   Journal of Crohns & Colitis

European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases

(2015) Axel U Dignass et al.   Journal of Crohns & Colitis

European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies

(2015) Vito Annese et al.   Journal of Crohns & Colitis

The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease

(2015) Marcus Harbord et al.   Journal of Crohns & Colitis

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis

(2015) Taku Kobayashi et al.   JOURNAL OF GASTROENTEROLOGY

Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis

(2014) D. Wolf et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases

(2014) Xavier Roblin et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis

(2014) Omoniyi J. Adedokun et al.   GASTROENTEROLOGY

Long-term Prognosis of Ulcerative Colitis and its Temporal Change Between 1977 and 2013: A Hospital-based Cohort Study from Korea

(2014) Ho-Su Lee et al.   Journal of Crohns & Colitis

Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience

(2013) D. Laharie et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

(2013) Remo Panaccione et al.   GASTROENTEROLOGY

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study

(2013) Simon P L Travis et al.   GUT

European consensus on the histopathology of inflammatory bowel disease

(2013) F. Magro et al.   Journal of Crohns & Colitis

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

(2013) Yasuo Suzuki et al.   JOURNAL OF GASTROENTEROLOGY

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Second-Generation Corticosteroids for the Treatment of Crohn’s Disease and Ulcerative Colitis: More Effective and Less Side Effects?

(2012) Chiara De Cassan et al.   DIGESTIVE DISEASES

Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study

(2012) William J. Sandborn et al.   GASTROENTEROLOGY

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing - ASCEND I and II combined analysis

(2011) G. R. Lichtenstein et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

(2011) W. Reinisch et al.   GUT

Ulcerative Colitis as A Progressive Disease: The Forgotten Evidence

(2011) Joana Torres et al.   INFLAMMATORY BOWEL DISEASES

Review article: what do patients with inflammatory bowel disease want for their clinical management?

(2010) N. WESTWOOD et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis

(2010) F. Hartmann et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis

(2009) William J. Sandborn et al.   GASTROENTEROLOGY

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

(2009) Laurent Beaugerie et al.   LANCET